公开(公告)号：US20130252885A1

公开(公告)日：2013-09-26

申请号：US13825665

申请日：2011-09-22

申请人： Barawkar Dinesh ,  Basu Sujay ,  Ramdas Vidya ,  Naykodi Minakshi ,  Patel Meena ,  Shejul Yogesh ,  Thorat Sachin ,  Panmand Anil

发明人： Barawkar Dinesh ,  Basu Sujay ,  Ramdas Vidya ,  Naykodi Minakshi ,  Patel Meena ,  Shejul Yogesh ,  Thorat Sachin ,  Panmand Anil

IPC分类号： C07D487/14 ,  A61K31/5377 ,  A61K31/519 ,  C07D519/00 ,  A61K45/06

CPC分类号： C07D487/14 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00

摘要： The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

摘要翻译： 本公开内容涉及式（I）的稠合三环化合物或其互变异构体，多晶型物，立体异构体，前药，溶剂合物或药学上可接受的盐或含有它们的药物组合物和将其作为A2A腺苷介导的病症和疾病的方法 受体拮抗剂。 本公开的化合物可用于治疗，预防或抑制可能通过腺苷A2A受体介导而改善的疾病和病症。 这些病症包括但不限于：帕金森病，不宁腿综合征，阿尔茨海默病，神经变性疾病，炎症，伤口愈合，真皮纤维化，夜间肌阵挛，脑缺血，心肌缺血，亨廷顿舞蹈病，多系统萎缩，皮质基底变性， 威尔逊病或基底节神经节的其他疾病，导致运动障碍，创伤后应激障碍，肝硬化，败血症，脊髓损伤，视网膜病变，高血压，社会记忆障碍，抑郁，神经保护，发作性睡眠或其他睡眠相关疾病，注意缺陷多动障碍 ，药物成瘾，创伤后应激障碍和血管损伤等。 本公开还涉及制备这些化合物的方法以及含有它们的药物组合物。